UnknownPhase 4

Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function

Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function in Newly-diagnosed Type 2 Diabetic Patients

Lead sponsor

Sun Yat-sen University

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

100

Study population

Type 2 diabetes

Eligibility highlights

•BMI 21-35

Primary endpoint

•Percentage of the patients who maintain glucose control 1 year after short

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01790308

Org study ID13450149260

Timeline

Milestones

Study first posted2013-02-13estimated

Last update posted2013-02-13estimated

Study start2013-02 (month precision)

Primary completion2014-12estimated (month precision)

Study completion2015-12estimated (month precision)

Assets

Investigational agents

Liraglutide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age20 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•newly diagnosed type 2 diabetes

•fasting blood glucose (FBG) level ranging from 7.0-16.7mmol/L

•body mass index (BMI) ranging from 21-35kg/m2

•antihypercaemic and antihyperlipidemic medication-naive patients

Exclusion criteria

•having any severe acute or chronic diabetic complications

•renal dysfunction, blood creatinine>150umol/L

•blood aminotransferase level rising up(more than 2 times of the upper normal limit of ALT)

•any severe cardiac disease including congestive cardiac failure, unstable angina or myocardial infarct in 12 months

•chronic or acute pancreatic disease

•severe systemic diseases or malignant tumor

•female patients incline to be pregnant

•being treated with corticosteriod, immunosuppressing drugs or cytotoxic drugs

•poor compliance

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

3 endpoints

Primary/protocol endpoint/low confidence

the percentage of the patients who maintain glucose control 1 year after short intensive therapy

Time frame:1 year

threshold achievement, improvement

Secondary/protocol endpoint/low confidence

the acute insulin response reflected β-cell function of different interventions in newly-diagnosed type 2 diabetic patients

Time frame:1 year

change from baseline, improvement

Secondary/protocol endpoint

the remission rate differ from interventions in newly-diagnosed type 2 diabetic patients

Time frame:1 year

categorical status, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.